Progenics Pharmaceuticals Inc (PGNX) Gross Profit Margin starting from the first quarter 2020 to first quarter 2019, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Progenics Pharmaceuticals Inc  (PGNX)


Progenics Pharmaceuticals Inc's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PGNX Gross Profit Margin (Mar 31 2020)
Q1 		(Dec 31 2019)
Q4 		(Sep 30 2019)
Q3 		(Jun 30 2019)
Q2 		(Mar 31 2019)
Q1
Y / Y Revenue Change 45.95 %
Seq. Revenue Change -58.69 %
Revenue In Millions $6.25
Gross Profit Margin 75.06 %
Gross Profit Margin Total Ranking # 643
Gross Profit In Millions $4.69
Y / Y Gross Profit Change -
Seq. Gross Profit Change -65.94 %


Commenting First Quarter 2020 Gross Profit Margin
Progenics Pharmaceuticals Inc experienced contraction in Gross Profit by -65.94 % to $6 millions and Revenue by -58.69 %, while Gross Profit Margin fell to 75.06 %, below company*s average Gross Profit Margin.


Observing first quarter 2020 results within Major Pharmaceutical Preparations industry 75 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 268 to 643.
Learn about Gross Margin
PGNX's Gross Profit Margin first quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 76
Healthcare Sector # 135
Overall # 625

Gross Profit Margin Statistics
High Average Low
96.86 % 87.76 % 54.34 %
(Mar 31 2013)   (Sep 30 2012)


PGNX Gross Income Trends • More of PGNX's Profitabilty Ratios • PGNX Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
PGNX's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
PGNX's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for PGNX's Competitors
Gross Profit Margin Profit Margin for Progenics Pharmaceuticals Inc's Suppliers
Gross Profit Margin Profit Margin for PGNX's Customers

You may also want to know
PGNX's Annual Growth Rates PGNX's Profitability Ratios PGNX's Asset Turnover Ratio PGNX's Dividend Growth
PGNX's Roe PGNX's Valuation Ratios PGNX's Financial Strength Ratios PGNX's Gross Profit Growth
PGNX's Roa PGNX's Inventory Turnover Ratio PGNX's Growth Rates PGNX's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2020, within Major Pharmaceutical Preparations Industry Gross Profit MarginMar 31 2020 MRQ Gross ProfitMar 31 2020 MRQ Revenue
Rigel Pharmaceuticals Inc  99.72 %$ 55.606  Millions$ 55.761  Millions
Ptc Therapeutics inc   99.71 %$ 68.059  Millions$ 68.259  Millions
Agios Pharmaceuticals Inc   99.39 %$ 86.565  Millions$ 87.098  Millions
Global Blood Therapeutics Inc.  99.04 %$ 13.983  Millions$ 14.118  Millions
Nabriva Therapeutics Plc  98.99 %$ 0.781  Millions$ 0.789  Millions
Omeros Corporation  98.87 %$ 23.270  Millions$ 23.537  Millions
Intercept Pharmaceuticals inc   98.83 %$ 71.800  Millions$ 72.652  Millions
Ionis Pharmaceuticals Inc   98.09 %$ 130.819  Millions$ 133.367  Millions
Corcept Therapeutics Inc  97.99 %$ 91.369  Millions$ 93.247  Millions
Avalo Therapeutics Inc   97.58 %$ 2.687  Millions$ 2.754  Millions
Ironwood Pharmaceuticals inc   97.20 %$ 77.704  Millions$ 79.943  Millions
Travere Therapeutics Inc   97.13 %$ 46.399  Millions$ 47.769  Millions
Acadia Pharmaceuticals Inc   96.89 %$ 87.269  Millions$ 90.068  Millions
Adamas Pharmaceuticals Inc  96.05 %$ 13.909  Millions$ 14.481  Millions
Siga Technologies Inc  95.84 %$ 2.511  Millions$ 2.620  Millions
Regeneron Pharmaceuticals Inc   95.69 %$ 1,749.400  Millions$ 1,828.200  Millions
Supernus Pharmaceuticals inc   95.63 %$ 90.824  Millions$ 94.976  Millions
Jazz Pharmaceuticals Plc  93.80 %$ 501.548  Millions$ 534.726  Millions
Intra cellular Therapies Inc   93.63 %$ 1.014  Millions$ 1.083  Millions
United Therapeutics Corporation  93.43 %$ 332.900  Millions$ 356.300  Millions
Serina Therapeutics Inc   93.40 %$ 0.481  Millions$ 0.515  Millions
Assertio Holdings inc   93.31 %$ 19.518  Millions$ 20.917  Millions
Emmaus Life Sciences Inc   93.13 %$ 6.476  Millions$ 6.954  Millions
Lexicon Pharmaceuticals Inc   92.90 %$ 7.431  Millions$ 7.999  Millions
Stemline Therapeutics Inc  92.78 %$ 8.232  Millions$ 8.873  Millions
Sage Therapeutics Inc   92.56 %$ 2.116  Millions$ 2.286  Millions
Nektar Therapeutics  92.46 %$ 46.762  Millions$ 50.573  Millions
Alexion Pharmaceuticals Inc   92.27 %$ 1,333.100  Millions$ 1,444.800  Millions
Verastem Inc   92.25 %$ 4.664  Millions$ 5.056  Millions
Gw Pharmaceuticals Plc  91.07 %$ 109.864  Millions$ 120.633  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.